Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Stifel Nicolaus

Stifel Nicolaus upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a buy rating in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage currently has $37.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Jefferies Financial Group upped their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Bank of America raised their price target on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. JPMorgan Chase & Co. dropped their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Denali Therapeutics in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and an average price target of $40.40.

Denali Therapeutics Stock Up 1.4 %

DNLI stock opened at $23.29 on Monday. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33. The business has a fifty day moving average of $26.21 and a two-hundred day moving average of $24.88. The stock has a market cap of $3.35 billion, a price-to-earnings ratio of -8.44 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the firm posted ($0.72) EPS. As a group, sell-side analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the sale, the director now directly owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the sale, the insider now directly owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This trade represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock valued at $2,474,440 in the last quarter. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. grew its position in shares of Denali Therapeutics by 163.7% in the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after buying an additional 24,767 shares during the last quarter. Candriam S.C.A. boosted its stake in Denali Therapeutics by 62.2% in the second quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock valued at $16,869,000 after acquiring an additional 278,621 shares in the last quarter. FMR LLC grew its holdings in shares of Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. Integral Health Asset Management LLC acquired a new stake in shares of Denali Therapeutics during the second quarter worth about $7,546,000. Finally, Algert Global LLC increased its position in shares of Denali Therapeutics by 82.4% during the third quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,975 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.